Cellara builds programmable cell and gene therapy platforms — from target discovery through clinical translation — for diseases with no durable treatment today.
Cellara's vector-design engine generates and screens thousands of candidate constructs computationally before a single one reaches the bench — cutting years off the traditional discovery timeline. Drag the model to inspect the structure.
AAV9 capsid delivering a functional gene copy to retinal pigment epithelium
Autologous CAR-T cells targeting a B-cell surface antigen
Lipid-nanoparticle mRNA restoring enzyme expression in hepatocytes
Ex vivo lentiviral correction of muscle progenitor cells
Allogeneic iPSC-derived NK cells engineered for tumor infiltration
Oral small molecule modulating pre-mRNA splicing
Liver-tropic AAV delivering a clotting factor transgene
Self-amplifying RNA platform for a single-dose prophylactic
Expanded tumor-infiltrating lymphocytes with cytokine support
Bifunctional degrader targeting an intracellular signaling node
Cellara was founded to close the gap between computational vector design and clinical translation — the platform, the manufacturing, and the trial operations all live under one roof.
Meet the teamWelcome to WordPress. This is your first post. Edit or delete it, then start writing!
We keep molecular targets confidential pre-patent, but we try to be transparent about the mechanism class…
Cell therapy's biggest bottleneck isn't the science. It's turning a bespoke, patient-specific product into something repeatable.